New biologic and targeted therapies are changing the landscape of prurigo nodularis care, offering sustained relief and ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

Medically reviewed by Susan Bard, MD Atopic dermatitis (AD), a common form of eczema, is a chronic (long-term) skin condition ...

Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

With positive Phase 3 data for HS, positive Phase 2 proof-of-concept data previously presented for Vitiligo, prurigo nodularis, and now CSU Povorcitinib solidifies itself as a potential new ...

The drug is approved for prurigo nodularis and atopic dermatitis. RBC described the launch as ahead of expectations and noted strong early uptake across both indications. Jefferies emphasized ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Barzolvolimab's Phase 3 trials target chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with mixed competitive prospects.

The FDA approved Nemluvio for use in patients with moderate to severe atopic dermatitis in December, following an initial approval in prurigo nodularis in August. Galderma is now facing off ...

Beyond CSU, Dupixent is approved in the US for certain cases of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis and chronic ...